| Adjuvant trastuzumab in HER2-positive breast cancer D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ... New England journal of medicine 365 (14), 1273-1283, 2011 | 3244 | 2011 |
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ... Journal of Clinical Oncology 25 (28), 4414-4422, 2007 | 1697 | 2007 |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008 | 1207 | 2008 |
| Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics BT Hennessy, AM Gonzalez-Angulo, K Stemke-Hale, MZ Gilcrease, ... Cancer research 69 (10), 4116-4124, 2009 | 1060 | 2009 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008 | 922 | 2008 |
| Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment MS Ewer, MT Vooletich, JB Durand, ML Woods, JR Davis, V Valero, ... Journal of Clinical Oncology 23 (31), 7820-7826, 2005 | 877 | 2005 |
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 855 | 2006 |
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ... Clinical cancer research 19 (19), 5533-5540, 2013 | 854 | 2013 |
| Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer DP Atchley, CT Albarracin, A Lopez, V Valero, CI Amos, ... Journal of Clinical Oncology 26 (26), 4282-4288, 2008 | 788 | 2008 |
| Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ... Journal of Clinical Oncology 19 (10), 2587-2595, 2001 | 754 | 2001 |
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ... Journal of Clinical Oncology 20 (7), 1800-1808, 2002 | 752 | 2002 |
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors V Guarneri, K Broglio, SW Kau, M Cristofanilli, AU Buzdar, V Valero, ... Journal of clinical oncology 24 (7), 1037-1044, 2006 | 747 | 2006 |
| Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer M Ayers, WF Symmans, J Stec, AI Damokosh, E Clark, K Hess, M Lecocke, ... Journal of clinical oncology 22 (12), 2284-2293, 2004 | 671 | 2004 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 666 | 2011 |
| Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype WF Symmans, C Wei, R Gould, X Yu, Y Zhang, M Liu, A Walls, ... Journal of Clinical Oncology 35 (10), 1049-1060, 2017 | 632 | 2017 |
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor … AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ... Clinical Cancer Research 13 (1), 228-233, 2007 | 603 | 2007 |
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ... Cancer research 68 (22), 9221-9230, 2008 | 591 | 2008 |
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ... Journal of clinical oncology 27 (34), 5700-5706, 2009 | 567 | 2009 |
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with … S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ... Journal of clinical oncology 28 (3), 453-459, 2010 | 543 | 2010 |
| Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer S Ruggiero, J Gralow, RE Marx, AO Hoff, MM Schubert, JM Huryn, B Toth, ... Journal of oncology practice 2 (1), 7-14, 2006 | 541 | 2006 |
